Biomedical Research Infrastructure Goes Global

Six institutions from Canada, the Czech Republic, Austria, France and Italy have now become official partners of the Infrafrontier consortium. With the participation of Canada, the consortium will be extended beyond Europe. The aim is to create a multinational research infrastructure for the phenotyping and archiving of mouse models of human diseases.

Helmholtz Zentrum München today announced that the Infrafrontier project, funded by the European Union, has been expanded to include six partners from Canada, the Czech Republic, Austria, France and Italy. The new partners will join the effort of the other 22 members of Infrafrontier in building up an international research infrastructure to improve open access to high-quality mouse models. Animal models have become an important tool in the study of complex human diseases such as diabetes, osteoporosis, asthma and depression, but also in the study of fundamental mechanisms such as speech development in humans. Colin McKerlie, spokesman of the Canadian partner, views the partnership as a "crucial step to successfully face one of the most interesting scientific challenges of the 21st century; to understand the function of every gene in the genome."

Professor Martin Hrabé de Angelis is director of the Institute of Experimental Genetics at Helmholtz Zentrum München and coordinates the EU Project Infrafrontier. "The international expansion facilitates the networking of the best scientists across the globe," Martin Hrabé de Angelis said. This opportunity is especially important to the Czech partners, as Prof. Radislav Sedlacek, programme coordinator for the Czech Center for Phenogenomics, stressed.

"We know that in the coming years we will be confronted with scientific tasks that cannot be solved with the infrastructure we currently have in Europe," Hrabé de Angelis went on to say. Infrafrontier will close this gap by expanding existing facilities and building new ones. A central coordination unit shall also be established. These endeavors will provide biomedical research with an international, open-access research infrastructure.

The partners in the Infrafrontier Consortium are the leading European systemic phenotyping centers (mouse clinics), the members of EMMA (European Mouse Mutant Archive) and research ministries and major funding agencies. New to Infrafrontier are the Czech Center for Phenogenomics and the Czech Republic's Ministry for Education, Youth and Sport, the Veterinary University of Vienna, the French institute INSERM (Institut National de la Santé et de la Recherche Médicale), the Italian Ministry of Labor, Health and Social Sciences and the Toronto Center for Phenogenomics. Altogether, 12 European countries and Canada now participate in Infrafrontier.

Infrafrontier is part of the ESFRI (European Strategy Forum on Research Infrastructures) roadmap, which outlines a plan to create research infrastructures of great scientific importance and pan-European interest, and which is therefore funded by the European Union.

For further information, please visit:
http://www.infrafrontier.eu

Most Popular Now

AI Catches One-Third of Interval Breast …

An AI algorithm for breast cancer screening has potential to enhance the performance of digital breast tomosynthesis (DBT), reducing interval cancers by up to one-third, according to a study published...

Great plan: Now We need to Get Real abou…

The government's big plan for the 10 Year Health Plan for the NHS laid out a big role for delivery. However, the Highland Marketing advisory board felt the missing implementation...

Researchers Create 'Virtual Scienti…

There may be a new artificial intelligence-driven tool to turbocharge scientific discovery: virtual labs. Modeled after a well-established Stanford School of Medicine research group, the virtual lab is complete with an...

From WebMD to AI Chatbots: How Innovatio…

A new research article published in the Journal of Participatory Medicine unveils how successive waves of digital technology innovation have empowered patients, fostering a more collaborative and responsive health care...

New AI Tool Accelerates mRNA-Based Treat…

A new artificial intelligence (AI) model can improve the process of drug and vaccine discovery by predicting how efficiently specific mRNA sequences will produce proteins, both generally and in various...

AI also Assesses Dutch Mammograms Better…

AI is detecting tumors more often and earlier in the Dutch breast cancer screening program. Those tumors can then be treated at an earlier stage. This has been demonstrated by...

RSNA AI Challenge Models can Independent…

Algorithms submitted for an AI Challenge hosted by the Radiological Society of North America (RSNA) have shown excellent performance for detecting breast cancers on mammography images, increasing screening sensitivity while...

AI could Help Emergency Rooms Predict Ad…

Artificial intelligence (AI) can help emergency department (ED) teams better anticipate which patients will need hospital admission, hours earlier than is currently possible, according to a multi-hospital study by the...

Head-to-Head Against AI, Pharmacy Studen…

Students pursuing a Doctor of Pharmacy degree routinely take - and pass - rigorous exams to prove competency in several areas. Can ChatGPT accurately answer the same questions? A new...

NHS Active 10 Walking Tracker Users are …

Users of the NHS Active 10 app, designed to encourage people to become more active, immediately increased their amount of brisk and non-brisk walking upon using the app, according to...

New AI Tool Illuminates "Dark Side…

Proteins sustain life as we know it, serving many important structural and functional roles throughout the body. But these large molecules have cast a long shadow over a smaller subclass...

Deep Learning-Based Model Enables Fast a…

Stroke is the second leading cause of death globally. Ischemic stroke, strongly linked to atherosclerotic plaques, requires accurate plaque and vessel wall segmentation and quantification for definitive diagnosis. However, conventional...